Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) is a multinational, randomized, controlled trial designed to compare the effects of prandial versus fasting glycemic control on risk for cardiovascular outcomes in patients with type 2 diabetes after acute myocardial infarction (AMI). RESEARCH DESIGN AND METHODS—Patients (type 2 diabetes, aged 30–75 years) were randomly assigned within 21 days after AMI to the 1) prandial strategy (PRANDIAL) (three premeal doses of insulin lispro targeting 2-h postprandial blood glucose <7.5 mmol/l) or the 2) basal strategy (BASAL) (NPH twice daily or insulin glargine once daily targeting fasting/premeal blood glucose <6.7 mmol/l). RESULTS—A total of 1,115 patients were randomly assigned (PRANDIAL n = 557; BASAL n = 558), and the mean patient participation after randomization was 963 days (range 1–1,687 days). The trial was stopped for lack of efficacy. Risks of first combined adjudicated primary cardiovascular events in the PRANDIAL (n = 174, 31.2%) and BASAL (n = 181, 32.4%) groups were similar (hazard ratio 0.98 [95% CI 0.8–1.21]). Mean A1C did not differ between the PRANDIAL and BASAL groups (7.7 ± 0.1 vs. 7.8 ± 0.1%; P = 0.4) during the study. The PRANDIAL group showed a lower daily mean postprandial blood glucose (7.8 vs. 8.6 mmol/l; P < 0.01) and 2-h postprandial blood glucose excursion (0.1 vs. 1.3 mmol/l; P < 0.001) versus the BASAL group. The BASAL group showed lower mean fasting blood glucose (7.0 vs. 8.1 mmol/l; P < 0.001) and similar daily fasting/premeal blood glucose (7.7 vs. 7.3 mmol/l; P = 0.233) versus the PRANDIAL group. CONCLUSIONS—Treating diabetic survivors of AMI with prandial versus basal strategies achieved differences in fasting blood glucose, less-than-expected differences in postprandial blood glucose, similar levels of A1C, and no difference in risk for future cardiovascular event rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated postchallenge (2-h oral glucose tolerance test) glucose values have been associated with increased cardiovascular risk independent of fasting plasma glucose in some epidemiologic studies, whereas intervention trials have not shown postprandial glucose to be a cardiovascular risk factor independent of A1C.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [73]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most of the large outcome trials conducted so far have been mostly based on preprandial glucose and A1C targets, with limited evidence of a long-term benefit of targeting PPG alone (49,50).”
From Targets for Glycemic Control (2018) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, manipulating prandial glucose levels failed to impact clinical outcome, and therefore, this remains an unresolved area.142,143”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [143]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, a randomized controlled trial in patients with known CVD found no CVD benefit of insulin treatment plans targeting postprandial glucose compared with those targeting preprandial glucose (73).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [73]
The cited source says what the claim attributes to it.
In the citing paper
“Elevated postchallenge (2-h oral glucose tolerance test) glucose values have been associated with increased cardiovascular risk independent of fasting plasma glucose in some epidemiologic studies, whereas intervention trials have not shown postprandial glucose to be a cardiovascular risk factor independent of A1C.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [73]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 2×
“The Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD) trial (21) demonstrated increased mortality with intensive glycemic goals (A1C of 6.4%), the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial (22) showed similar cardiovascular outcomes wi…”
InfluentialDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 1×
“A similar separation in glycemic control was noted in the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study (18), in which the primary composite cardiovascular end point failed to reach significance between therapies, but the secondary composite end point did reach significance.”
ResultStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,724
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
“Additionally, an RCT in patients with known CVD found no CVD benefit of insulin regimens targeting postprandial glucose compared with those targeting preprandial glucose (102).”
BackgroundStandards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
“Additionally, an RCT in patients with known CVD found no CVD benefit of insulin regimens targeting postprandial glucose compared with those targeting preprandial glucose (104).”
BackgroundStandards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
“Additionally, an RCT in patients with known CVD found no CVD benefit of insulin regimens targeting postprandial glucose compared with those targeting preprandial glucose (92).”
Background(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
“Additionally, a randomized controlled trial in patients with known CVD found no CVD benefit of insulin regimens targeting postprandial glucose compared with those targeting preprandial glucose (70).”
BackgroundLow Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?
Martín-Timón, I. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i4.444 · Cited by 976
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
“Additionally, a randomized controlled trial in patients with known CVD found no CVD benefit of insulin regimens targeting postprandial glucose compared with those targeting preprandial glucose (61).”
Background6. Glycemic Targets: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s006 · Cited by 762
“regimens targeting postprandial glucose compared with those targeting preprandial glucose (74).”
Background6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s006 · Cited by 744
“Additionally, a randomized controlled trial in patients with known CVD found no CVD benefit of insulin regimens targeting postprandial glucose compared with those targeting preprandial glucose (49).”
Background6. Glycemic Targets: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s006 · Cited by 684
6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s006 · Cited by 655
“Additionally, a randomized controlled trial in patients with known CVD found no CVD benefit of insulin regimens targeting postprandial glucose compared with those targeting preprandial glucose (42).”
Background(2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.10.013 · Cited by 609
Glycaemic variability in diabetes: clinical and therapeutic implications
Ceriello, A., Monnier, L., & Owens, D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30136-0 · Cited by 588
Impact of postprandial glycaemia on health and prevention of disease
Blaak, E. E., Antoine, J. ‐., Benton, D., Björck, I., Bozzetto, L., Brouns, F., Diamant, M., Dye, L., Hulshof, T., Holst, J. J., et al. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01011.x · Cited by 477
Glucose Variability; Does It Matter?
Siegelaar, S. E., Holleman, F., Hoekstra, J. B. L., & DeVries, J. H. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0021 · Cited by 409
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., & Wetterslev, J. (2011) · BMJ · doi:10.1136/bmj.d6898 · Cited by 386
Cavalot, F., Pagliarino, A., Valle, M., Di Martino, L., Bonomo, K., Massucco, P., Anfossi, G., & Trovati, M. (2011) · Diabetes Care · doi:10.2337/dc10-2414 · Cited by 322
“In fact, patients of the HEART2D trial were not representative of thewhole type 2 diabetic population, being a subset of very-highrisk patients randomized within 21 days after a myocardial infarction (19).”
BackgroundHemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T. P., & Wetterslev, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub4 · Cited by 291
Glycemic Variability and Diabetes Complications: Does It Matter? Of Course It Does!
Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc14-2898 · Cited by 282
“entire spectrum of GV) and did not show benefit after acutemyocardial infarction in subjects with type 2 diabetes using a prandial insulin strategy compared with those using basal insulin (23).”
BackgroundMethodAmerican Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s009 · Cited by 271
“Additionally, a randomized controlled trial in patients with known CVD found no CVD benefit of insulin regimens targeting postprandial glucose compared with those targeting preprandial glucose (60).”
BackgroundUdell, J. A., Cavender, M. A., Bhatt, D. L., Chatterjee, S., Farkouh, M. E., & Scirica, B. M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00044-3 · Cited by 254
Glucose Variability: Where It Is Important and How to Measure It
DeVries, J. H. (2013) · Diabetes · doi:10.2337/db12-1610 · Cited by 235
“In a reanalysis of the HEART2D (Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus) study (19), in which glucose variability is notably lower in the mealtime-related insulin arm than in the basal insulin arm (Fig.”
MethodThe Task Force on diabetes, P.-D. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114525548 · Cited by 236
‘Glycaemic variability’: a new therapeutic challenge in diabetes and the critical care setting
Ceriello, A., & Ihnat, M. A. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02967.x · Cited by 233
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
Holman, R. R., Sourij, H., & Califf, R. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60794-7 · Cited by 227
Service, F. J. (2013) · Diabetes · doi:10.2337/db12-1396 · Cited by 221
“Although the Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) trial, which compared prandial to basal glucose control, was (38) not specifically designed to evaluate glycemic variability, inferences can be drawn from the narro…”
BackgroundCardiovascular disease in diabetes, beyond glucose
Eckel, R. H., Bornfeldt, K. E., & Goldberg, I. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.001 · Cited by 212
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s008 · Cited by 215
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s009 · Cited by 205
“Additionally, a randomized controlled trial in patients with known CVD found no CVD benefit of insulin regimens targeting postprandial glucose compared with those targeting preprandial glucose (48).”
BackgroundHemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T. P., & Wetterslev, J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub3 · Cited by 203
RetractedGlycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?
Saisho, Y. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151018381 · Cited by 195
Castagno, D., Baird-Gunning, J., Jhund, P. S., Biondi-Zoccai, G., MacDonald, M. R., Petrie, M. C., Gaita, F., & McMurray, J. J. V. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.07.030 · Cited by 190
Postprandial Hyperglycemia and Glycemic Variability
Standl, E., Schnell, O., & Ceriello, A. (2011) · Diabetes Care · doi:10.2337/dc11-s206 · Cited by 183
“Finally, the HEART2D Trial (57) was also a negative trial in terms of the effectiveness of targeting postprandial hyperglycemia by a specific insulin regimen in diabetic patients after myocardial infarction.”
BackgroundGuideline for management of postmeal glucose in diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.08.002 · Cited by 183
Wright, L. A.-C., & Hirsch, I. B. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0029 · Cited by 178
“Numerous studies link PPG with CV disease and CV events with a plausible pathophysiology and report that targeting PPG rather than FPG lowers CV risk,(69) although others have reported no difference in CV event rates when targeting PPG.(70) PPG is helpful to assess meal-induced glucose excursions and efficacy of DM tr…”
BackgroundDiabetes mellitus and stroke: A clinical update
Tun, N. N., Arunagirinathan, G., Munshi, S. K., & Pappachan, J. M. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.235 · Cited by 177
Glucose variability: An emerging target for the treatment of diabetes mellitus
Frontoni, S., Di Bartolo, P., Avogaro, A., Bosi, E., Paolisso, G., & Ceriello, A. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.09.007 · Cited by 174
“A second supporting element is based on the consideration that an increase in postprandial glycemia may have a particularly harmful effect on the onset of cardiovascular complications [40], a concept supported by the STOP-NIDDM primary prevention study [41], but not by the HEART2D secondary prevention study [42], whic…”
ResultPasquel, F. J., Gianchandani, R., Rubin, D. J., Dungan, K. M., Anzola, I., Gomez, P. C., Peng, L., Hodish, I., Bodnar, T., Wesorick, D., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30402-8 · Cited by 168
Penno, G., Solini, A., Bonora, E., Fondelli, C., Orsi, E., Zerbini, G., Morano, S., Cavalot, F., Lamacchia, O., Laviola, L., et al. (2013) · Diabetes Care · doi:10.2337/dc12-2264 · Cited by 168
“However, a prospective study specifically addressing this issue did not show any effect of within-day glucose fluctuations on cardiovascular events (8).”
BackgroundRSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
“[184] TZDs have demonstrated beneficial effects in attenuating dyslipidaemia commonly observed in patients with chronic T2DM.”
BackgroundInfluentialGlycemic variability in the development of cardiovascular complications in diabetes
Nusca, A., Tuccinardi, D., Albano, M., Cavallaro, C., Ricottini, E., Manfrini, S., Pozzilli, P., & Di Sciascio, G. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3047 · Cited by 158
“A re‐analysis of HEART‐2D study, in which GV was evaluated in T2D patients with history of recent acute MI, introduced controversial data: a prandial insulin strategy demonstrated lower intraday GV compared with a basal insulin regimen even with similar HbA1c levels, but this GV difference did not result in a signific…”
MethodClinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
“A few robust clinical trials have explored the impact of reducing PPG on vascular complications, with evidence of beneficial impacts on both microvascular (eg, retinopathy) and macrovascular (eg, cardiovascular) disease (4, 5).”
Benefits and harms of intensive glycemic control in patients with type 2 diabetes
Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J. G., Zuñiga-Hernandez, J. A., & McCoy, R. G. (2019) · BMJ · doi:10.1136/bmj.l5887 · Cited by 152
Luk, A. O. Y., Ma, R. C. W., Lau, E. S. H., Yang, X., Lau, W. W. Y., Yu, L. W. L., Chow, F. C. C., Chan, J. C. N., & So, W. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2404 · Cited by 146
“following a cardiac event, found no difference in outcome between patients assigned to receive basal insulin and those receiving prandial insulin [20].”
BackgroundBergenstal, R. M. (2015) · Diabetes Care · doi:10.2337/dc15-0099 · Cited by 140
Alpha-glucosidase inhibitors 2012 – cardiovascular considerations and trial evaluation
Standl, E., & Schnell, O. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441524 · Cited by 155
Pharmacologic management of type 2 diabetes
Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., Sherifali, D., Woo, V., & Yale, J.-F. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.021 · Cited by 138
Postprandial hyperglycemia on vascular endothelial function: mechanisms and consequences
Mah, E., & Bruno, R. S. (2012) · Nutrition Research · doi:10.1016/j.nutres.2012.08.002 · Cited by 149
“[15] Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, et al.”
BackgroundMonnier, L., Colette, C., Mas, E., Michel, F., Cristol, J., Boegner, C., & Owens, D. R. (2009) · Diabetologia · doi:10.1007/s00125-009-1574-6 · Cited by 144
“In the Hyperglycemia and its Effects After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) Study [43], the inhibitory effect of insulin on activation of oxidative stress might explain why smaller glucose fluctuations with prandial insulin regimens did not impr…”
BackgroundInfluentialImran, S. A., RABASA-LHORET, R. P. R., & Ross, S. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.016 · Cited by 148
Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., Ceriello, A., & Esposito, K. (2011) · Diabetes Care · doi:10.2337/dc10-1710 · Cited by 127
“A sensitivity analysis excluding one trial (36) gave significant results (OR 2.”
BackgroundInfluentialRSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017
Bajaj, S. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0604-7 · Cited by 125
Imran, S. A., Agarwal, G., Bajaj, H. S., & Ross, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.030 · Cited by 113
Glycemic Variability: Both Sides of the Story
Ceriello, A., & Kilpatrick, E. S. (2013) · Diabetes Care · doi:10.2337/dcs13-2030 · Cited by 111
“The Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes (HEART2D) study specifically targeted PPG (and therefore glucose variability) in order to reduce cardiovascular events (26).”
BackgroundNishimura, R., Tanaka, Y., Koiwai, K., Inoue, K., Hach, T., Salsali, A., Lund, S. S., & Broedl, U. C. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0169-9 · Cited by 106
Kowaltowski, A. J., & Abdulkader, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-50968-2_9 · Cited by 106
Clinical Implications of Glucose Variability: Chronic Complications of Diabetes
Jung, H. S. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.2.167 · Cited by 103
Serious Cardiovascular Outcomes in Diabetes: The Role of Hypoglycemia
Yakubovich, N., & Gerstein, H. C. (2011) · Circulation · doi:10.1161/circulationaha.110.948489 · Cited by 111
on behalf of the ADAG Study Group, Borg, R., Kuenen, J. C., Carstensen, B., Zheng, H., Nathan, D. M., Heine, R. J., Nerup, J., Borch-Johnsen, K., & Witte, D. R. (2011) · Diabetologia · doi:10.1007/s00125-010-1918-2 · Cited by 100
“However, a recent randomised clinical trial in patients with type 2 diabetes mellitus and CVD did not support an added benefit of targeting control of PPG for subsequent CVD events [4].”
Pramlintide and the treatment of diabetes: a review of the data since its introduction
Younk, L. M., Mikeladze, M., & Davis, S. N. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.581663 · Cited by 100
“Opposing evidence does exist, with some studies showing no additional benefit of targeting PPG [14].”
BackgroundSchernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1702-3 · Cited by 97
“The Hyperglycemia and its Effect after Acute Myocardial Infarction on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (HEART2D) Study failed to show any benefit of prandial vs basal insulin on cardiovascular outcomes following acute myocardial infarction [54].”
BackgroundCavalot, F. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12140 · Cited by 95
“Finally, the HEART2D study randomized patients with T2DM who recently had myocardial infarctions to receive prandial or basal insulin therapy in order to assess the effect on CV events [36].”
MethodUtility of different glycemic control metrics for optimizing management of diabetes
Kohnert, K.-D. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.17 · Cited by 94
Update on biomarkers of glycemic control
Krhač, M., & Lovrenčić, M. V. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i1.1 · Cited by 93
Associations Between Features of Glucose Exposure and A1C
Borg, R., Kuenen, J. C., Carstensen, B., Zheng, H., Nathan, D. M., Heine, R. J., Nerup, J., Borch-Johnsen, K., Witte, D. R., & on behalf of the ADAG Study Group (2010) · Diabetes · doi:10.2337/db09-1774 · Cited by 93
“, pregnant women [24] and individuals with impaired glucose tolerance [25] or type 2 diabetes post-AMI [26]), which have addressed the issue with different methods and have had conflicting results.”
ResultKloecker, D. E., Davies, M. J., Khunti, K., & Zaccardi, F. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3286 · Cited by 105
Siegelaar, S. E., Kerr, L., Jacober, S. J., & Devries, J. H. (2011) · Diabetes Care · doi:10.2337/dc10-1684 · Cited by 89
“It was designed to investigate possible differences between two insulin treatment strategies on time until first combined cardiovascular event (a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for acute coronary syndrome) (9).”
BackgroundSelf-citationMonnier, L., Colette, C., & Owens, D. R. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.962 · Cited by 89
“(a) significant difference was observed between fasting and postprandial plasma glucose (paired t test); (b) significantly different from all other quintiles (ANOVA); (c) significantly different from quintile 5 (ANOVA); ANOVA, analysis of variance (Adapted from [68])”
MethodInfluentialUltrafast-Acting Insulins: State of the Art
Heinemann, L., & Muchmore, D. B. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600402 · Cited by 89
Postprandial and Basal Glucose in Type 2 Diabetes: Assessment and Respective Impacts
Monnier, L., Colette, C., & Owens, D. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0239 · Cited by 88
Monnier, L., Colette, C., & Owens, D. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.014 · Cited by 91
Glycemic variability and diabetes retinopathy: A missing link
Hsu, C.-R., Chen, Y., & Sheu, W. H. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.11.013 · Cited by 86
Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality
Selvin, E., Rawlings, A. M., Lutsey, P. L., Maruthur, N. M., Pankow, J. S., Steffes, M. W., & Coresh, J. (2015) · Diabetes · doi:10.2337/db15-0607 · Cited by 84
“HDL cholesterol, mg/dL 48 (39, 60) 48 (39, 61) 43 (36, 57) 44 (35, 54) 43 (35, 52)”
BackgroundRaz, I., Ceriello, A., Wilson, P. W., Battioui, C., Su, E. W., Kerr, L., Jones, C. A., Milicevic, Z., & Jacober, S. J. (2011) · Diabetes Care · doi:10.2337/dc10-2375 · Cited by 78
“Lower fasting blood glucose and greater nocturnal hypoglycemia in the older subgroup compared with the total HEART2D trial population (1) may explain the disparity between the two analyses.”
BackgroundMethodResultInfluentialSelf-citationMadsbad, S. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.09.019 · Cited by 84
“study, because the population at very high risk of CVD had been well treated, in terms of numerous therapies to control their cardiovascular risk factors [60, 61].”
BackgroundPathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies
Gerich, J. (2013) · International Journal of General Medicine · doi:10.2147/ijgm.s51665 · Cited by 77
“In the HEART2D (Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus) study, the risk of a first primary cardiovascular event in patients with type 2 diabetes after acute myocardial infarction was not significantly different for patients tr…”
ResultCurrent perspectives on cardiovascular outcome trials in diabetes
on behalf of the D&CVD EASD Study Group, Schnell, O., Rydén, L., Standl, E., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0456-8 · Cited by 74
“Raz I, et al. Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia.”
ResultInfluentialSchernthaner, G. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0748-7 · Cited by 80
“basal insulin on cardiovascular outcomes in patients with T2DM following acute MI [47].”
BackgroundGlycemic variability: Clinical implications
Kota, S., Satya Krishna, S., & Modi, K. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.113751 · Cited by 74
“The occurrence of various microvascular and macrovascular complications in diabetes is attributed by various studies to hyperglycemia and dysglycemia (peaks and nadirs).[7-11] Several pathophysiological mechanisms were put forward,[12,13] unifying the two main mechanisms: Excessive protein glycation end products and a…”
BackgroundHirshberg, B., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s202 · Cited by 76
“The aim of the Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (HEART2D) study was to demonstrate a difference between two insulin strategies—one targeting postprandial hyperglycemia and the other targeting fasting and premeal hypergly…”
Self-citationThe Assessment of Glycemic Variability and Its Impact on Diabetes-Related Complications: An Overview
Weber, C., & Schnell, O. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0043 · Cited by 72
“94 Apparently it needs a more complex treatment strategy, covering the glucose profile of an entire day.”
Marx, N., McGuire, D. K., Perkovic, V., Woerle, H.-J., Broedl, U. C., von Eynatten, M., George, J. T., & Rosenstock, J. (2017) · Diabetes Care · doi:10.2337/dc17-0068 · Cited by 72
The glucose triad and its role in comprehensive glycaemic control: current status, future management
Ceriello, A. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02517.x · Cited by 78
Penno, G., Solini, A., Zoppini, G., Orsi, E., Fondelli, C., Zerbini, G., Morano, S., Cavalot, F., Lamacchia, O., Trevisan, R., et al. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-98 · Cited by 68
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
Saisho, Y. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030923 · Cited by 82
Monnier, L., & Colette, C. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30003-9 · Cited by 78
“Regarding the negative results obtained by retrospective analysis of the DCCT datasets [34,35] and prospective analysis of the HEART2D study [36], it should be noted that, in both trials, patients with diabetes were treated with insulin, a hormone that exerts antioxidant [39], anti-inflammatory and antithrombotic acti…”
MethodResultHemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., & Wetterslev, J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub2 · Cited by 69
RetractedGlycaemic variability: The under‐recognized therapeutic target in type 1 diabetes care
Wilmot, E. G., Choudhary, P., Leelarathna, L., & Baxter, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13842 · Cited by 72
“In T2DM, investigators of the HEART2D study could not show any CV benefits as the result of tightly controlling variations in post-prandial glucose.(42) However, recent publications have highlighted a growing understanding of GV as a key determinant of glycaemic control and are begining to establish a link between GV…”
BackgroundSottero, B., Gargiulo, S., Russo, I., Barale, C., Poli, G., & Cavalot, F. L. (2015) · Medicinal Research Reviews · doi:10.1002/med.21349 · Cited by 83
Yu, P. C., Bosnyák, Z., & Ceriello, A. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.12.009 · Cited by 68
Gamble, J., Chibrikov, E., Twells, L., Midodzi, W. K., Young, S. W., MacDonald, D., & Majumdar, S. R. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30316-3 · Cited by 63
Tay, J., Thompson, C. H., & Brinkworth, G. D. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-121214-104422 · Cited by 61
“The HEART2D (Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus) study compared insulin strategies targeting PPG or FBG in 1,115 individuals with T2DM (184).”
Bloomfield, H. E., Greer, N. L., Newman, D. R., MacDonald, R. H., Carlyle, M. H., FITZGERALD, P. J., Rutks, I. R., & Wilt, T. J. (2012) · Cited by 89
Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes
Standl, E., Schnell, O., & McGuire, D. K. (2016) · Circulation Research · doi:10.1161/circresaha.116.306924 · Cited by 59
Treating Coronary Disease and the Impact of Endothelial Dysfunction
Matsuzawa, Y., Guddeti, R. R., Kwon, T.-G., Lerman, L. O., & Lerman, A. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2014.10.004 · Cited by 57
Metadata
- Authors
- Raz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., & Jacober, S. J.
- Affiliations
- Hadassah Medical Center (IL)
- Emory University (US)
- Medical University of Silesia (PL)
- Medical University of Białystok (PL)
- Endocrinology, Diabetes and Metabolic Diseases, University Hospital Dubrava, Zagreb, Croatia
- Cardiology, Herzzentrum Ludwigshafen, Ludwigshafen, Germany
- Medical Department, Bajcsy-Zsilinszky Teaching Hospital, Budapest, Hungary
- Eli Lilly (United States) (US)
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-03-01
- Volume
- 32
- Issue
- 3
- Pages
- 381-386
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2646013
- OpenAlex
- W2172111876
- Cited by
- 351
- References
- 26
- Citations by year
- 2025: 5 · 2024: 9 · 2023: 2 · 2022: 5 · 2021: 12 · 2020: 13 · 2019: 18 · 2018: 20 · 2017: 22 · 2016: 28 · 2015: 36 · 2014: 25 · 2013: 35 · 2012: 24
- FWCI
- 29.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- type 2 diabetes, acute myocardial infarction, insulin lispro, basal insulin, postprandial blood glucose, glycemic excursions, cardiovascular outcomes, HbA1c, lack of efficacy
- MeSH terms
- Insulin Glargine, Adult, Aged, Body Weight, Cardiovascular System, Diabetes Mellitus, Type 2, Drug Administration Schedule, Fasting, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Risk Factors, Treatment Outcome, Postprandial Period, Insulin, Long-Acting, Insulin Lispro
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.